A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL-Reference-Cited by-同舟云学术

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

Published:2008-01-17 Issue:7 Volume:22 Page:1456-1459
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Best O G,Gardiner A C,Majid A,Walewska R,Austen B,Skowronska A,Ibbotson R,Stankovic T,Dyer M J S,Oscier D G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2405092.pdf

Reference8 articles.

1. Oscier DG, Wade R, Orchard J, Davis Z, Best G, Morilla A et al. Prognostic factors in the UK LRF CLL4 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: 299.

2. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443.

3. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175–3182.

4. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448–5457.

5. Carter A, Lin K, Sherrington PD, Pettitt AR . Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425–428.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The molecular map of CLL and Richter's syndrome;Seminars in Hematology;2024-04

2. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro;Leukemia & Lymphoma;2024-01-16

3. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer;Journal of Ovarian Research;2023-06-27

4. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro;2022-03-07

5. LCK Regulates Homologous Recombination DNA Repair and Targeting Enhances PARPi Utility in HR Proficient Ovarian Cancer;SSRN Electronic Journal;2022